New hope for half-match bone marrow transplant in blood cancer

Share this content:

A small study has demonstrated an improved process for making half-matched bone marrow or stem cell transplants for persons with blood cancer more successful.

Although the use of a genetically fully matched donor has yielded the best results in bone marrow transplant, many patients lack a fully matched related or unrelated donor. However, nearly every patient has a half-matched, or haploidentical relative. The successful use of haploindentical donors would greatly expand the number of donors available to every patient, yet half-matched bone marrow or stem cell transplants have been largely unsuccessful.

Neal Flomenberg, MD, chair of the department of medical oncology at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, and colleagues recently tested their new two-step approach to haploidentical hematopoietic stem cell transplantation. The 27 patients participating in the phase I/II trial had been diagnosed with leukemia, lymphoma, or myelodysplasia (median age: 52 years).

First, after undergoing radiation therapy, the patients were given a specified dose of T cells from their half-matched family donor—the person's parent, sibling, or child. This was followed by administration of the drug cyclophosphamide to enhance tolerance to the infused donor T cells.

In the second step of the transplant, patients were given a dose of the donor's stem cells to help normalize the patient's blood counts and further strengthen his or her new immune system.

As Flomenberg's team reported in the journal Blood, 17 of the 27 patients were alive 6 months posttransplant. Based on a follow-up of 28 to 56 months, 3-year probability of overall survival for the whole cohort was 48%, increasing to 75% for those who had been in remission at the time of transplantation.

The researchers called these outcomes encouraging, particularly in good-risk patients, and suggested that this procedure be further explored.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs